TrialLeukemia research2019

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Aaron T Gerds et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.